NCT05485571

Efficacy of Combined Microneedling With Methotrexate in Treatment of Alopecia Areata

Status unknown NA Last updated 3 August 2022

What this trial tests

NA trial testing derma pen in Alopecia Areata in 30 participants. Status unknown.

Timeline

1 August 2022

Primary endpoint
1 February 2023

1 February 2023

Quick facts

Lead sponsor	Sohag University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 August 2022
Primary completion	1 February 2023
Estimated completion	1 February 2023
Sites	1 location across Egypt

Drugs / interventions tested

• derma pen

Conditions studied

• Alopecia Areata — all drugs for Alopecia Areata →

Sponsor

Sohag University

Who can join

Adults 18 to 40, any sex, with Alopecia Areata. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Alopecia areata (AA) is a common cause of non-cicatricial hair loss It is the second-most frequent non-scarring alopecia, after androgenic alopecia.

The prevalence of the disease is 0.2% in the general population with higher prevelance in younger (21-40 years of age) patients but no significant difference in incidence between males and females.

Several treatment options such as corticosteroids, anthralin, topical minoxidil, immunotherapy, and systemic therapy are commonly used with varying response . Unfortunately the traditional treatment options are frequently disappointing Available treatments may induce regrowth but do not modify the disease course .

Methotrexate (MTX) is a folic acid analog that binds to the dihydrofolate reductase enzyme, blocking the formation of tetrahydrofolate and so inhibits purine and pyrimidine metabolism and consequently nucleic acid synthesis. It acts as an immunosuppressant used in the treatment of several skin diseases Systemic MTX has been used in the treatment of AA, with satisfactory results. Microneedling is a minimally invasive procedure that utilizes multiple fine needles to create micropunctures in the skin.The act of creating these two to four cell-wide puncture holes triggers neovascularization, release of growth factors, and stimulates the expression of Wnt proteins. it has specifically been demonstrated to increase hair regrowth in alopecia via the release of platelet-derived growth factor, epidermal growth factors and activation of the hair bulge, all of which are triggered by the wound healing response .Increased expression of Wnt proteins, namely Wnt3a and Wnt10b, is also evident following microneedling. These particular proteins have been demonstrated to stimulate dermal papillae stem cells and hair growth.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Delivery Strategies of siRNA Therapeutics for Hair Loss Therapy.
   Jin SE, Sung JH. · · 2024 · cited 1× · PMID 39062852 · DOI 10.3390/ijms25147612